




Implementation of NCTN External Evaluational Working Group & CTAC Recommendations

Meg Mooney, MD
Chief, Clinical Investigations Branch
Cancer Therapy Evaluation Program, DCTD, NCI



CTAC Meeting
July 12, 2017


Structure of New National Clinical Trials Network

- 5 US groups (4 adult & 1 pediatric) and 1 Canadian Collaborating group
- Centralized functions for operational efficiencies & optimized use of scientific innovations
- 30 Lead Academic Participating Sites (LAPS) provide leadership in development, accrual & trial conduct of adult group trials
- Large Phase 2 & all Phase 3 trial concepts evaluated by NCI Disease-specific Steering Committees
- 7 Integrated Translational Science awards to enhance incorporation of translational science into trials

≈ 2400 enrolling sites across North America (plus international sites)

LEGEND:

- **Centralized Functions:**
 - Centralized Institutional Review Board
 - Cancer Trials Support Unit
 - RT/Imaging Core Center
 - NCI Disease-Specific Steering Committees
 - Common Data Mgt with System Central Hosting
- 30 Lead Academic Participating Sites (LAPS)
- Operations
- Statistics & Data Management
- Tumor Banks
- Member Sites



<http://www.cancer.gov/clinicaltrials/nctn>


Vision for Transformation to New NCTN – 2014 and Beyond

- Facilitate consolidation of former Cooperative Group Program to provide essential infrastructure for NCI trials in treatment, control, screening, diagnosis, & prevention across all NCI clinical research programs
- Launch trials rapidly & complete accrual per defined guidelines in Network
- Promote user-friendly, harmonized processes & ease collaborations
- Reinvigorate trial portfolio
 - Prioritize trials & incorporate innovative science & design into studies
 - Continue focus on questions not well supported in commercial environment
 - Provide a functional platform to perform large scale testing of increasingly smaller subsets of molecularly-defined cancers and incorporate precision medicine trials into portfolio

NCTN Mix of Trials Continues to be Diverse

- Precision medicine umbrella/basket trials with targeted agents & combination of targeted agents
- Combined modality trials, studies not addressed by private sector, and studies in rare cancers & rare subsets of more common cancers, & trials in special patient populations (AYA, elderly, HIV+ pts)
- Studies with public-private partnerships, including licensing trials for new drugs/new indications
- NCTN Program continues to report trial outcomes that result in new drug indications & changes in standard of care (selected list of accomplishments over the first 3 yrs provided in concept document)

Map of Participating Sites Enrolling Patients in NCTN Trials – First 3 Years of Program



NCTN Accrual by Trial Phase & Type

First 3 Years of Program

Intervention/Cohort Accrual & Screening on Study Accrual for All NCTN Studies with at Least 1 Patient Enrolled: Sorted by Phase and NCTN Grant Year										
ADULT AND PEDIATRIC NCTN TRIALS	Grant Year 1 (3/1/14 to 2/28/15)				Grant Year 2 (3/1/15 to 2/29/16)			Grant Year 3 (3/1/16 to 2/28/2017)		
	NCTN Trial Phase	# Studies	Intervention & Cohort Accrual	Screening on Study Accrual	# Studies	Intervention & Cohort Accrual	Screening on Study Accrual	# Studies	Intervention & Cohort Accrual	Screening on Study Accrual
	Phase 1	12	153	0	6	158	0	7	77	3
	Phase 1/2	14	237	0	11	308	0	11	162	9
	Phase 2	72	2,056	221	83	2,162	1,561	98	2,355	5,168
	Phase 2/3	14	615	225	16	918	1,031	15	1,070	1,235
	Phase 3	75	12,573	1,119	69	10,364	1,029	64	10,492	1,083
	Imaging	5	243	0	4	77	0	3	46	0
	Other	3	280	3	3	1,835	22	4	2,642	11
	Pilot	3	99	0	2	41	0	1	4	0
TOTAL	198	16,256	1,568	194	15,863	3,643	203	16,848	7,509	
Total # Unique Pts Screened or Treated				17,343				18,524		

Accrual for 3 years prior to start of the NCTN for the former Cooperative Group Program

TYPE/FY	FY2011	FY2012	FY2013
ADULT	15,925	17,130	17,813
PEDIATRIC	3,850	4,034	3,997
TOTAL	19,775	21,164	21,810

CTAC Subcommittee Working Group

External Review of NCTN - Recommendations

- **Revise NCTN Goal Statement:** Include early phase Precision Medicine trials

The goal of the NCI National Clinical Trials Network (NCTN) is to provide an integrated, multi-center program for late-phase, clinical treatment trials (i.e., randomized phase 2 & phase 3 trials) and investigation of new advanced imaging techniques across a broad range of cancers and modalities, as well as to conduct early phase studies needed for development of definitive trials, especially umbrella/basket trials and rare tumor trials for discovery when an extensive, national patient catchment area is required.

The NCTN Program promotes the evaluation of single and multi-modality treatments, including surgery and radiotherapy in combination with novel agents, and maintains a commitment to the conduct of trials in special populations (e.g., children, adolescents, young adults, and underserved populations) and rare tumors. This focus allows NCTN Program to complement, rather than duplicate, research conducted by the private sector.

CTAC Subcommittee Working Group

External Review of NCTN - Recommendations

- **On Network Collaboration:**
 - Groups & NCI should continue to prioritize important strategic issues
 - Maintain high rate of cross-Group collaboration & coordination with NCI
 - Continue to share best practices across Groups
 - Specify roles & responsibilities of patient advocates

- **On Efficiency & External Collaboration:**
 - Continue to monitor timelines for trial development
 - Identify mechanisms for career development & increase diversity in leadership
 - Continue to facilitate minority/underserved accrual
 - Continue NCI's commitment to collaborations (industry, federal, international)

- **Longer-Term Recommendations:**
 - Too early to evaluate fully some NCTN components (ITSCs, IROC, LAPS)
 - Promote best practices for Group operations & include in future Guidelines

Overview 6 RFAs - NCTN Program Re-Issue

Network Component	Mechanism (Duration)	Est. Max # Grants	Multiple PI Option?
NCTN Group Operations Centers	U10 (6 Yrs)	5	Yes
Associated NCTN Group Statistics & Data Mgt Centers	U10 (6 Yrs)	5	Yes
Canadian Collaborating Clinical Trials Network	U10 (6 Yrs)	1	Yes
Lead Academic Participating Sites (LAPs)	U10 (6 Yrs)	30 to 35 (With ability to go out for additional LAPs in 3 years, if funding permits)	Yes
RT and Imaging Core Services Center (IROC)	U24 (6 Yrs)	1	Yes
Integrated Translational Science Center Awards (ITSAs)	U10 (6 Yrs)	7	Yes

NCTN Reissue RFA Funding Request

Recommended Budget &
Actual NCTN Budget Provided for 5-Year Grant Period 2014-2019

New Reissue TC Budget
Request for 6-Year RFAs

Category for Base Division Set-Aside for Network Program	Annual Total Cost Request FY14 to FY18 (≈ 20,000 Tx Trial Accruals)	Actual Annual Total Cost Budget Provided for NCTN 5-Year Grant Period 2014 to 2019	New Annual Total Cost Budget Request for NCTN 6-Year Grant Period 2019 to 2024
Funding Based on FY2011 Levels:			
Cooperative Grp Operations & Statistics/Data Mgt Centers, and Associated Program & Site Support	\$ 152,644,335	\$ 151,000,000	\$151,000,000
Request Based on New Funding Model & Translational Science Support:			
<u>Increased</u> Capitation to fund accrual & biospecimen collections for NCTN Trials	\$ 21,600,000	\$0	\$20,000,000
Translational Science Support	\$ 4,000,000	\$0	\$0
New Funding Subtotal:	\$ 25,600,000	\$0	\$20,000,000
Grand Total:	\$ 178,244,335	\$ 151,000,000	\$171,000,000

Tentative Timeline – Competitive Renewal NCTN Program RFAs

General Feedback on Current System	July – November 2016
Internal/External Review Initial Program	November 2016 – May 2017
BSA Concept Review	June 2017
DEA & NIH Review FOA	July – September 2017
New FOAs Released/Published	September 2017
Competing Applications Due Date	January 2018
Review New Competing Applications	Spring-Early Summer 2018
NCAB Review	September 2018
New Award Date	March 1, 2019